Literature DB >> 9131254

Molecular mechanisms of genetic polymorphisms of drug metabolism.

U A Meyer1, U M Zanger.   

Abstract

One of the major causes of interindividual variation of drug effects is genetic variation of drug metabolism. Genetic polymorphisms of drug-metabolizing enzymes give rise to distinct subgroups in the population that differ in their ability to perform certain drug biotransformation reactions. Polymorphisms are generated by mutations in the genes for these enzymes, which cause decreased, increased, or absent enzyme expression or activity by multiple molecular mechanisms. Moreover, the variant alleles exist in the population at relatively high frequency. Genetic polymorphisms have been described for most drug metabolizing enzymes. The molecular mechanisms of three polymorphisms are reviewed here. The acetylation polymorphism concerns the metabolism of a variety of arylamine and hydrazine drugs, as well as carcinogens by the cytosolic N-acetyltransferase NAT2. Seven mutations of the NAT2 gene that occur singly or in combination define numerous alleles associated with decreased function. The debrisoquine-sparteine polymorphism of drug oxidation affects the metabolism of more than 40 drugs. The poor metabolizer phenotype is caused by several "loss of function" alleles of the cytochrome P450 CYP2D6 gene. On the other hand, "ultrarapid" metabolizers are caused by duplication or amplification of an active CYP2D6 gene. Intermediate metabolizers are often heterozygotes or carry alleles with mutations that decrease enzyme activity only moderately. The mephenytoin polymorphism affects the metabolism of mephenytoin and several other drugs. Two mutant alleles of CYP2C19 have so far been identified to cause this polymorphism. These polymorphisms show recessive transmission of the poor or slow metabolizer phenotype, i.e. two mutant alleles define the genotype in these individuals. Simple DNA tests based on the primary mutations have been developed to predict the phenotype. Analysis of allele frequencies in different populations revealed major differences, thereby tracing the molecular history and evolution of these polymorphisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131254     DOI: 10.1146/annurev.pharmtox.37.1.269

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  68 in total

Review 1.  Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Authors:  Valentine J Burroughs; Randall W Maxey; Richard A Levy
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

2.  Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes.

Authors:  Jian Yang; Chunshu Hao; Dongfang Yang; Deshi Shi; Xiulong Song; Xiaofei Luan; Gang Hu; Bingfang Yan
Journal:  Toxicol Lett       Date:  2010-06-09       Impact factor: 4.372

Review 3.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Association of CYP2D6 100 C > T and 2850 C > T polymorphisms with generalized tonic clonic seizures among Indians.

Authors:  C C Soundararajan; A Adhin; M Tripathi; H K Prasad; S Jain; S Vivekanandhan
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

5.  CYP2D6 polymorphisms in patients with porphyrias.

Authors:  Jimena V Lavandera; Victoria E Parera; Alcira Batlle; Ana María Buzaleh
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

6.  Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema.

Authors:  Nicola Marchi; Giulia Betto; Vincent Fazio; Quinyuan Fan; Chaitali Ghosh; Andre Machado; Damir Janigro
Journal:  Epilepsia       Date:  2009-01-21       Impact factor: 5.864

7.  Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.

Authors:  Siew Hua Gan; Rusli Ismail; Wan Aasim Wan Adnan; Wan Zulmi
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

8.  Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.

Authors:  Eva Maria Staehli Hodel; Chantal Csajka; Frédéric Ariey; Monia Guidi; Abdunoor Mulokozi Kabanywanyi; Socheat Duong; Laurent Arthur Decosterd; Piero Olliaro; Hans-Peter Beck; Blaise Genton
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

Review 9.  Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Authors:  Tanya E Froehlich; James J McGough; Mark A Stein
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 10.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.